title: Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.
authors.affiliation: Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: R A
authors.initials: RA
authors.lastname: Abdelrahman
authors.affiliation: Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: K H
authors.initials: KH
authors.lastname: Begna
authors.affiliation: Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: A
authors.initials: A
authors.lastname: Al-Kali
authors.affiliation: Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: W J
authors.initials: WJ
authors.lastname: Hogan
authors.affiliation: Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: M R
authors.initials: MR
authors.lastname: Litzow
authors.affiliation: Division of Hematology and Department of Medicine, Mayo Clinic, Rochester, MN, USA.
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001549:Benzamides / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053614:Janus Kinase 2 / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000276:immunology / Q000628:therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C546012:N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; C540383:ruxolitinib; C507924:JAK2 protein, human; D053614:Janus Kinase 2